The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years’ experience at a single centre

• Published in: Journal of clinical neuroscience Vol. 18; no. 3; pp. 329 - 333
• Main Authors: Parkinson, Jonathon F, Afaghi, Vahid, Payne, Cathy A, Buckland, Michael E, Brewer, Janice M, Biggs, Michael T, Little, Nicholas S, Wheeler, Helen R, Cook, Raymond J, McDonald, Kerrie L
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.03.2011
• Subjects: Adult; Aged; Anaplastic oligodendroglioma; Brain Neoplasms - genetics; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Chemosensitivity; Chemotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1 - genetics; Chromosomes, Human, Pair 19 - genetics; Drug Resistance, Neoplasm - genetics; Female; Glioma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Loss of Heterozygosity; Male; Middle Aged; Neurology; Oligodendroglioma; Oligodendroglioma - genetics; Oligodendroglioma - mortality; Oligodendroglioma - pathology; Prognosis; Proportional Hazards Models; Survival; Tumor Suppressor Protein p53 - metabolism; Young Adult; Chemotherapy; Prognosis; Glioma; Chemosensitivity; Survival; Anaplastic oligodendroglioma; Oligodendroglioma
• ISSN: 0967-5868; 1532-2653
• DOI: 10.1016/j.jocn.2010.07.101

Abstract The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs . 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p = 0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs . 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.